To verify whether the STAT3 signaling pathway is indispensable for lncRNA HAR1A-mediated NSCLC cell proliferation in vitro, we treated NSCLC cells infected with lenti-shHAR1A with a STAT3 inhibitor. Here, HAR1A is linked to non-small cell lung carcinoma.